Bioceres Crop Solutions (NASDAQ:BIOX) Posts Earnings Results, Misses Estimates By $0.10 EPS

Bioceres Crop Solutions (NASDAQ:BIOXGet Free Report) announced its quarterly earnings data on Monday. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.10), MarketWatch Earnings reports. Bioceres Crop Solutions had a net margin of 3.56% and a return on equity of 5.37%. The business had revenue of $104.70 million during the quarter, compared to analyst estimates of $96.59 million. During the same quarter last year, the firm posted ($0.12) EPS.

Bioceres Crop Solutions Price Performance

Shares of Bioceres Crop Solutions stock traded up $0.13 on Wednesday, hitting $11.13. The company’s stock had a trading volume of 2,813 shares, compared to its average volume of 59,141. Bioceres Crop Solutions has a 52-week low of $9.76 and a 52-week high of $15.13. The company has a quick ratio of 0.89, a current ratio of 1.39 and a debt-to-equity ratio of 0.43. The firm has a fifty day moving average price of $12.14 and a 200-day moving average price of $11.82. The company has a market capitalization of $704.85 million, a P/E ratio of 55.00 and a beta of 0.42.

Institutional Investors Weigh In On Bioceres Crop Solutions

Several institutional investors and hedge funds have recently made changes to their positions in the business. Advisor Group Holdings Inc. lifted its holdings in Bioceres Crop Solutions by 66.9% in the 4th quarter. Advisor Group Holdings Inc. now owns 2,242 shares of the company’s stock valued at $27,000 after purchasing an additional 899 shares in the last quarter. Lazard Asset Management LLC purchased a new position in Bioceres Crop Solutions in the 4th quarter valued at about $49,000. Goldman Sachs Group Inc. purchased a new position in Bioceres Crop Solutions in the 2nd quarter valued at about $176,000. Sei Investments Co. purchased a new position in Bioceres Crop Solutions in the 2nd quarter valued at about $221,000. Finally, UBS Group AG purchased a new position in Bioceres Crop Solutions in the 2nd quarter valued at about $302,000. 13.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on BIOX. Lake Street Capital cut their target price on shares of Bioceres Crop Solutions from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday. Roth Mkm reissued a “buy” rating and issued a $31.00 price objective on shares of Bioceres Crop Solutions in a research note on Tuesday. Four research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Bioceres Crop Solutions has a consensus rating of “Buy” and an average target price of $23.67.

View Our Latest Report on BIOX

Bioceres Crop Solutions Company Profile

(Get Free Report)

Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates in three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier and higher yielding crops.

Featured Stories

Earnings History for Bioceres Crop Solutions (NASDAQ:BIOX)

Receive News & Ratings for Bioceres Crop Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioceres Crop Solutions and related companies with's FREE daily email newsletter.